Podcasts about guidelines

Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as compared to small molecule generics remain limited.  

In June 2022, Maxwell's legal team submitted a 77-page sentencing memorandum to the U.S. District Court in Manhattan requesting a significant downward variance from both the Probation Department's recommendation and the federal Sentencing Guidelines. While the probation office had proposed a 20-year sentence (240 months), Maxwell's attorneys argued she should receive only 51 to 63 months in prison. They maintained that Maxwell should not be punished as a proxy for Jeffrey Epstein, emphasizing he was the principal orchestrator of the crimes and that Maxwell had never before been charged with wrongdoing until her association with him resurfaced. Her defense also cited her difficult and traumatic childhood, abusive father, and the death threats she continues to face as aggravating circumstances warranting leniency.Prosecutors forcefully opposed the request, urging the court instead to impose a prison term within the Guidelines range—between 30 to 55 years—based on Maxwell's “pivotal role” in grooming and recruiting vulnerable young girls for Epstein. They highlighted her lack of remorse, failure to accept responsibility, and the profound and enduring harm caused to numerous victims. The prosecutors made clear that Maxwell's privileged background offered no mitigation given the extreme gravity of her crimes.to contact me:bobbycapucci@protonmail.comsource:https://www.theguardian.com/us-news/2022/jun/15/ghislaine-maxwell-sex-trafficking-sentence

In today's episode, Jessie and Anita talk all about cardiovascular training in pregnancy. Is it safe for pregnant women to do cardiovascular exercise or interval training in pregnancy? We will break it down in an evidence-based fashion - what CAN you do? What's safe? What does the evidence say? Tune in to today's episode to find out!- - - - - - - - -If you liked this episode of To Birth and Beyond, tell your friends! Find us on iTunes and Spotify to rate/review/subscribe to the show.Want more? Visit www.ToBirthAndBeyond.com, join our Facebook group (To Birth and Beyond Podcast), and follow us on Instagram @tobirthandbeyondpodcast! Thanks for listening and joining the conversation!Resources and References Join Jessie's free, LIVE, Build Beta TestShow Notes 0:55 - Join Jessie's Build Beta Test!2:28 - Jessie and Anita introduce today's episode3:19 - What we know for sure…5:15 - The benefits of cardiovascular exercise in pregnancy8:04 - What kind of exercise “counts” as cardio?10:49 - Let's talk about heart rate!15:21 - If you are coming back to cardiovascular activity in pregnancy after a break, or starting from scratch…18:25 - Key safety points when talking about cardiovascular and interval training work in pregnancy22:22 - Episode wrap up

The Japan Fair Trade Commission on Tuesday released guidelines for information technology giants, such as Google LLC and Apple Inc., regarding smartphone apps, ahead of the full implementation in December of a new law to promote competition in the app market.

The document "ISO 45003:2021 Gestión de la seguridad y salud en el trabajo Seguridad y salud psicológicas en el trabajo Directrices para la gestión de los riesgos psicosociales" is identical to the International Standard ISO 45003:2021. It was developed by the technical committee CTN 81 Seguridad y salud en el trabajo.This standard provides guidelines for managing psychosocial risks and promoting well-being at work. It is intended to be used in conjunction with ISO 45001, which outlines requirements and guidance for planning, implementing, reviewing, evaluating, and improving an Occupational Health and Safety (OHS) management system.The primary goal of this document is to enable organizations to prevent work-related injuries and health deterioration in their workers and other interested parties, and to promote well-being in the workplace. It is applicable to organizations of all sizes and across all sectors for the development, implementation, maintenance, and continuous improvement of safe and healthy workplaces.Key Concepts:Psychosocial Risk is defined as the combination of the likelihood of exposure to psychosocial hazards related to work and the severity of injury and health deterioration that these hazards can cause.Psychosocial Hazards are related to how work is organized, social factors at work, and aspects of the work environment, equipment, and hazardous tasks. Examples are detailed in the sources.Well-being at Work is the fulfillment of a worker's physical, mental, social, and cognitive needs and expectations related to their work. It can also contribute to the quality of life outside of work and relates to all aspects of working life.The terms "psychological health" and "mental health" are considered interchangeable for the purposes of this document.Impact and Benefits of Managing Psychosocial Risks:Negative impacts for workers can include poor health conditions (e.g., cardiovascular disease, musculoskeletal disorders, diabetes, anxiety, depression, sleep disorders), unhealthy behaviors (e.g., substance misuse), and reduced job satisfaction, engagement, and productivity.Negative impacts for organizations can include increased costs due to absenteeism, staff turnover, reduced product/service quality, recruitment and training expenses, workplace investigations and litigation, and damage to the organization's reputation.Effective management of psychosocial risk can lead to positive outcomes such, as improved worker engagement, increased productivity, increased innovation, and organizational sustainability.Core Elements of Psychosocial Risk Management within an OHS Management System:Context of the Organization (Chapter 4): Organizations should understand external factors (e.g., supply chain pressure, economic conditions, technological changes, workforce mobility, public health issues) and internal factors (e.g., organizational structure, culture, management style, commitment to psychological health, workforce characteristics) that can affect their OHS management system and psychosocial risk management. They also need to understand the needs and expectations of workers and other interested parties.Leadership and Worker Participation (Chapter 5):Planning (Chapter 6):Support (Chapter 7):Operation (Chapter 8):Performance Evaluation (Chapter 9):Improvement (Chapter 10):

Not all toys are created equal!! Make sure you know which ones are WORTH your time and which ones you might need to DITCH!Do you want the details on how to choose the right toys for your baby AND at each stage??To find out what to look for, this episode has ALL you need!I sat down with Rachel and Jessica, founders of the All Things Sensory Podcast! We did a deep dive into the best kinds of sensory toys, developmental milestones to keep an eye out for, and SO MUCH MORE!This episode spills on:- Educational toys for infants 0-12 months- How do toys affect child development?- Baby container usage- What is the average age a baby starts walking?- What are the best developmental toys for babies?- Baby toys that are bad for development- DIY sensory baby toys- Guidelines for choosing developmentally appropriate toys- How to help baby developmentAnd more!----------------------------------------------------------------------------IMPORTANT LINKS:•Crunchi Makeup and Skincare HERE          ◦ Use Code ADVOCATE10 for 10% off!•Shop Laila's Clean Makeup Bag Staples HERE•Truly Free Home- Toxin Free Laundry Detergent and Cleaning Supplies HERE          ◦ Use Code LEARNINGTOMOM for 30% off!Connect with Rachel and Jessica HERE----------------------------------------------------------------------------Montessori baby toys diy, sensory baby toys diy, baby toys developmental stages, baby toys infant, baby toys less than 6 months, baby toys developmental, baby toys learning, baby toys newborn to 6 months, baby toys non-toxic, baby toys natural, baby toys high quality, baby toys sensory, baby toys toddler, baby toys under 1 year, baby toys year old, baby toys under 3 months, baby toys 3-6 months, baby toys 0-3, baby toys 0-6, baby toys 4-6 months, baby toys 10 months, baby toys 12 months, baby toys 7-12 months, baby toys 8-12 months, baby toys 5 months montessori, baby toys, baby toys to encourage rolling, baby toys to encourage standing, baby toys to help sit up, baby toys for development, baby toys for 2-month old, baby toys for 9-month old, baby toys for 4-month old, baby toys for 1-year old, baby toys for 6 month old, baby toys for 3 month old, baby toys to encourage crawling, baby toys to help crawl, baby toys to help stand, baby toys to help walk, what toys should a pediatrician recommend, what toys should you buy a newborn, what should be baby's first toy, what are the first toys for babies, should a 4 month-old be reaching for toys, what should a 4-month old be playing with, what toys should a 4 month-old have, what toys can a 4 month-old have, when should you start plkaying with toys with your baby, does a 2-month old need toys, should a 2-month old have toys, what are baby sensory toys, what are the best baby toys, what are baby toys used for, what are good baby toys, what baby toys do I really need, what are montessori baby toys, how do baby toys help development, what toys should 1 year old have, what are good learning toys for 1 year old, educational toys for one year old baby, Mom podcast, parenting podcast, First time mom podcast,  motherhood podcast, postpartum podcast, infant podcast, newborn care podcast, new baby podcast, pregnancy podcast, how to parent, parenting tips, parenting advice, 2 month old, 3 month old, 4 month old, 5 month old, 6 month old, 7 month old, 8 month old, 9 month old, 10 month old, 11 month old, 12 month old

This week's show covers managed bond accounts, sources of returns, what to do with inherited accounts, and lots of emails!

Japan's Defense Ministry on Monday unveiled guidelines aimed at enhancing the country's defense capabilities in the space domain through cooperation between the public and private sectors.

This week's show covers managed bond accounts, sources of returns, what to do with inherited accounts, and lots of emails!

July 27, 2025 - Sunday AM Sermon   FROM "CLACK" TO "CLICK"  Neal Pollard    Introduction    A. God's Guidelines for Navigating Marriage Turbulence:     1. Marriage is ________________________     2. Marriage doesn't have to be _________ into, but if we do, we must follow God's                               ____________                                          3. Marriage is for ____________ and ___________ God-given ___________     4. Marriage is ___________ participated in by two ____________    B. How Can We Pull Out Of ____________?    I. _______________________     A. What Are Issues That __________ Good _______________?        B. Healthy _____________ Starts With ____________, _____________, And           ______________     C. Make Sure You Devote Sufficient ____________ to ______________    II. ___________________    III. __________________    IV. __________________    V. _____________ WITH ________________    Conclusion    A. Are You "____________" Each Other Or Constantly ____________? You Decide!   Duration 40:36

With the increase in the public's attention to all aspects of brain health, neurologists need to understand their role in raising awareness, advocating for preventive strategies, and promoting brain health for all. To achieve brain health equity, neurologists must integrate culturally sensitive care approaches, develop adapted assessment tools, improve professional and public educational materials, and continually innovate interventions to meet the diverse needs of our communities. In this BONUS episode, Casey Albin, MD, speaks with Daniel José Correa, MD, MSc, FAAN and Rana R. Said, MD, FAAN, coauthors of the article “Bridging the Gap Between Brain Health Guidelines and Real-world Implementation” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Correa is the associate dean for community engagement and outreach and an associate professor of neurology at the Albert Einstein College of Medicine Division of Clinical Neurophysiology in the Saul Korey Department of Neurology at the Montefiore Medical Center, New York, New York. Dr. Said is a professor of pediatrics and neurology, the director of education, and an associate clinical chief in the division of pediatric neurology at the University of Texas Southwest Medical Center in Dallas, Texas. Additional Resources Read the article: Bridging the Gap Between Brain Health Guidelines and Real-world Implementation Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Guests: @NeuroDrCorrea, @RanaSaidMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. This exclusive Continuum Audio interview is available only to you, our subscribers. We hope you enjoy it. Thank you for listening. Dr Albin: Hi all, this is Dr Casey Albin. Today I'm interviewing Dr Daniel Correa and Dr Rana Said about their article on bridging the gap between brain health guidelines and real-world implementation, which they wrote with Dr Justin Jordan. This article appears in the June 2025 Continuum issue on disorders of CSF dynamics. Thank you both so much for joining us. I'd love to just start by having you guys introduce yourselves to our listeners. Rana, do you mind going first? Dr Said: Yeah, sure. Thanks, Casey. So, my name is Rana Said. I'm a professor of pediatrics and neurology at the University of Texas Southwestern Medical Center in Dallas. Most of my practice is pediatric epilepsy. I'm also the associate clinical chief and the director of education for our division. And in my newer role, I am the vice chair of the Brain Health Committee for the American Academy of Neurology. Dr Albin: Absolutely. So just the right person to talk about this. And Daniel, some of our listeners may know you already from the Brain and Life podcast, but please introduce yourself again. Dr Correa: Thank you so much, Casey for including us and then highlighting this article. So yes, as you said, I'm the editor and the cohost for the Brain and Life podcast. I do also work with Rana and all the great members of the Brain Health Initiative and committee within the AAN, but in my day-to-day at my institution, I'm an associate professor of neurology at the Albert Einstein College of Medicine in the Montefiore Health System. I do a mix of general neurology and epilepsy and with a portion of my time, I also work as an associate Dean at the Albert Einstein College of Medicine, supporting students and trainees with community engagement and outreach activities. Dr Albin: Excellent. Thank you guys both so much for taking the time to be here. You know, brain health has really become this core mission of the AAN. Many listeners probably know that it's actually even part of the AAN's mission statement, which is to enhance member career fulfillment and promote brain health for all. And I think a lot of us have this kind of, like, vague idea about what brain health is, but I'd love to just start by having a shared mental model. So, Rana, can you tell us what do you mean when you talk about brain health? Dr Said: Yeah, thanks for asking that question. And, you know, even as a group, we really took quite a while to solidify, like, what does that even mean? Really, the concept is that we're shifting from a disease-focused model, which we see whatever disorder comes in our doors, to a preventative approach, recognizing that there's a tremendous interconnectedness between our physical health, our mental health, cognitive and social health, you know, maintaining our optimal brain function. And another very important part of this is that it's across the entire lifespan. So hopefully that sort of solidifies how we are thinking about brain health. Dr Albin: Right. Daniel, anything else to add to that? Dr Correa: One thing I've really liked about this, you know, the evolution of the 2023 definition from the AAN is its highlight on it being a continuous state. We're not only just talking about prevention of injury and a neurologic condition, but then really optimizing our own health and our ability to engage in our communities afterwards, and that there's always an opportunity for improvement of our brain health. Dr Albin: I love that. And I really felt like in this article, you walked us through some tangible pillars that support the development and maintenance of this lifelong process of maintaining and developing brain health. And so, Daniel, I was wondering, you know, we could take probably the entire time just to talk about the five pillars that support brain health. But can you give us a pretty brief overview of what those are that you outlined in this article? Dr Correa: I mean, this was one of the biggest challenges and really bundling all the possibilities and the evidence that's out there and just getting a sense of practical movement forward. So, there are many organizations and groups out there that have formed pillars, whether we're calling them seven or eight, you know, the exact number can vary, but just to have something to stand on and move forward. We've bundled one of them as physical and sleep health. So really encouraging towards levels of activity and not taking it as, oh, that there's a set- you know, there are recommendations out there for amount of activity, but really looking at, can we challenge people to just start growing and moving forward at their current ability? Can we challenge people to look at their sleep health, see if there's an aspect to improve, and then reassess with time? We particularly highlight the importance of mental health, whether it's before a neurologic condition or a brain injury occurs or addressing the mental health comorbidities that may come along with neurologic conditions. Then there's of course the thing that everyone thinks about, I think, with brain health in terms of is cognitive health. And you know, I think that's the first place that really enters either our own minds or as we are observers of our elder individuals in our family. And more and more there has been the highlight on the need for social interconnectedness, community purpose. And this is what we include as a pillar of social health. And then across all types of neurologic potential injuries is really focusing on the area of brain injury. And so, I think the area that we've often been focused as neurologists, but also thinking of both the prevention along with the management of the condition or the injury after it occurs. Dr Albin: Rana, anything else to add to that? That's a fantastic overview. Dr Said: Daniel, thank you for- I mean, you just set it up so beautifully. I think the other thing that maybe would be important for people to understand is that as we're talking through a lot of these, these are individual. These sound like very individual-basis factors. But as part of the full conversation, we also have to understand that there are some factors that are not based on the individual, and then that leads to some of the other initiatives that we'll be talking about at the community and policy levels. So, for example, if an individual is living in an area with high air pollution. Yes, we want them to be healthy and exercise and sleep, but how do we modify those factors? What about lead leaching from our aging pipes or even infectious diseases? So, I think that outside of our pillars, this is sort of the next step is to understand what is also at large in our communities. Dr Albin: That's a really awesome point. I love that the article really does shine through and that there are these individual factors, and then there there's social factors, there's policy factors. I want to start just with that individual because I think so many of our patients probably know, like, stress management, exercise, sleep, all of that stuff is really important. But when I was reading your article, what was not so obvious to me was, what's the role that we as neurologists should play in advocating? And really more importantly, like, how should we do that? And again, it struck me that there are these kind of two issues at play. And one is that what Daniel was saying that, you know, a lot of our patients are coming because they have a problem, right? We are used to operating in this disease-based care, and there's just limited time, competing clinical demands. If they're not coming to talk about prevention, how do we bring that in? And so Rana, maybe I'll start with you just for that question, you know, for the patients who are seeing us with a disease complaint or they're coming for the management of a problem, how are you organizing this at the bedside to kind of factor in a little bit about that preventative brain health? Dr Said: You know, I think the most important thing at the bedside is, one, really identifying the modifiable risk factors. These have been well studied, we understand them. Hypertension, diabetes, smoking, weight management. And we know that these definitely are correlative. So is it our role just to talk about stroke, or should we talk about, how are you managing your blood pressure? Health education, if there was one major cornerstone, is elevating health literacy for everyone and understanding that patients value clear and concise information about brain health, about modifiable risk factors. And the corollary to that, of course, are what are the resources and services? I completely understand---I'm a practicing clinician---the constraints that we have at the bedside, be it in the hospital or in our clinics. And so being the source of information, how are we referring our families and individuals to social workers, community health worker support, and really partnering with them, food banks, injury prevention programs, patient advocacy organizations? I think those are really ways that we can meet the impacts that we're looking at the bedside that can feel very tangible and practical. Dr Albin: That's really excellent advice. And so, I'd like to ask a follow-up question. With your knowledge of this, trying to get more multidisciplinary buy-in from your clinic so that you really have the support to get these services that are so critically important. And how do you do that? Dr Said: Yeah, I think it's, one, being a champion. So, what does a champion mean? It means that somebody has to decide this is really important. And I think we all realize that we're not the only ones in the room who care about this. We're all in this, and we all care about it. But how do we champion it and carry it through? And so that's the first. Second you find your partnerships: your social workers, your case managers, your other colleagues. And then what is the first-level entry thing that you can do? So for example, I'm a pediatric epileptologist. One of the things we know is that in pediatric epilepsy, depression and anxiety are very strong comorbidities. So, before we get to the point where a child is in distress, every single one of our epilepsy patients who walks in the door over the age of twelve has an age-appropriate screener that is given to them in both English and Spanish. And we assess it and we determine stratifying risk. And then we have our social workers on the back end and we decide, is this a child who needs resources? Is this a child who needs to be walked to the emergency room, escorted? And anything in between. And I think that that was a just a very tangible example of, every single person can do this and ask about it. And through the development of dot phrases and clear protocols, it works really well. Dr Albin: I love that, the way that you're just being mindful. At every step of the way, we can help people towards this lifelong brain health. And Daniel, you work with an adult population. So I wonder, what are your tips for bringing this to a different patient population? Dr Correa: Well, I think---adult or child---one thing that we often are aware of with so many of the other things that we're doing in bedside or clinic room counseling, but we don't necessarily think of in this context of brain health, is, remember all the people in the room. So, at the bedside, whether it's in the ICU, discharge counseling, the initial admission, the whole family is often involved and really concerned about the active issue. But you can look for opportunities- we often try to counsel and support families about the importance of their own sleep and rest and highlighting it not just as being there for their family member, but highlighting it to them as a measure of their own improvement of their brain health. So, looking at ways where, one, I try to find, is there something I can do to support and educate the whole family about their brain health? And then- and with an epilepsy, or in many other situations, I try to look for one comorbidity that might be a pillar of brain health to address that maybe I wasn't already thinking. And then I consider, is there an additional thing that they wouldn't naturally connect to their epilepsy or their headaches that I can bring in for them to work on? You know, we can't often give people twelve different things to work on, and they'd just feel like, okay like, you have no realistic understanding of my life. But if we can just highlight on one, and remind them that there can be many more ways to improve their health and to follow up either with us as their neurologist or their future primary care doctors to address those additional needs. Again, I would really highlight the importance of a multidisciplinary approach and looking for opportunities. We've too often, I feel, relied on primary care as being the first line for addressing unmet social health needs. We know that so many people, once they have a neurologic condition or the potential, even, of a neurologic condition, they're concerned about dementia or something, they may view us, as their neurologist, as their most important provider. And if they don't have the resource of time and money to show up at other doctors, we may be the first one they're coming to. And so, tapping into your institution's resources and finding out, are there things that are available to the primary care services that for some reason we're not able to get on the inpatient side or the outpatient side? Referring to social workers and care workers and showing that our patients have an independent need, that they're not somehow getting captured by the primary care doctors. Dr Albin: I really love that. I think that we- just being more invested and just being ready to step into that role is really important. I was noticing in this article, you really call that being a brain health ambassador, being really mindful, and I will direct all of our listeners to Figure 3, which really captures what practitioners can do both at the bedside, within their local community, and even at the professional society level, to really advocate for policies that promote brain wellness. Rana, at the very beginning of this conversation, you noted, you know, this is not just an individual problem. This really is something that is a component of our policy and the structure of our local communities. I really loved in the article, there's a humility that this cannot be just a person-by-person bedside approach, that this is a little bit determined by the social determinants of health. And so, Rana, can you walk us through a little bit of what are the social determinants of health, and why are these so crucially important when we think about brain health for all? Dr Said: Yeah, social determinants of health are a really key factor that it looks at, what are the health factors that are environmental; for example, that are not directly like what your blood pressure is, what, you know, what your BMI is, that definitely impact our health outcomes. So, these include environmental things like where people are born, where they live, where they learn, work, play, worship, and age. It encompasses factors like your socioeconomic status, your education, the neighborhoods where you are living, definitely healthcare access. And then all of this is in a social and community context. We know that the impact of social determinants of health on brain health are profound for the entire lifespan and that- so, for example, if someone is from a disadvantaged background or that leads to chronic stress, they can have limited access to healthcare. They can have greater risk of exposure to, let's say, environmental toxins, and all of that will shape how their brain health is. Violence, for example. And so, as we think about how we're going to target and enhance brain health, we really have to understand that these are vulnerable populations, special high-risk populations, that often have a disproportionate burden of neurologic disorders. And by identifying them and then developing targeted interventions, it promotes health equity. And it really has to be done in looking at culturally- ethnocultural-sensitive healthcare education resources, thinking about culturally sensitive or adaptive assessment tools that work for different populations so that these guidelines that we have, that we've already identified as being so valuable, can be equitably applied, which is one crucial component of reducing brain health risk factors. And lastly, at the neighborhood level, this is where we really rely on our partnerships with community partners who really understand their constituents and they understand how to have the special conversations, how to enhance brain health through resource utilization. And so, this is another plug for policy and resources. Dr Albin: I love that. And thinking about the neighborhood and the policy levels and all the things that we have to do. Daniel, I'd like to ask you, is there anything else you would add? Dr Correa: Yeah, you know, so I really wanted to come back to this thing is that often and unfortunately, in the beginning understanding of social determinants of health, they're thought of as a positive or a negative factor, and often really negative. These are just facts. They're aspects about our community, our society, and some of them may be at the individual level. They're not at fault of any individual or community, or even our society. They're just the realities. And when someone has a factor that may predict a health disparity or an unmet social need---I wanted to come back to that concept and that term---one or two positive factors that are social determinants of health for that individual are unmet social needs. It's a point of promise. It's a potential to be addressed. And seeking ways to connect them with community services, social work, caregivers, these are ways where- that we can remove a barrier to, so that the possibility of the recommendations that we're used to doing, giving recommendations about medications and management, can be fully appreciated for that person. And the other aspect is, like brain health, this is a continuous state. The social determinants of health may be different for the child, the parent, and the elderly family member in the household, and there might be some that are shared across them. And when one of those individuals has a new medical illness or a new condition, a stroke, and now has a mobility limitation, that may change a social determinant of health for that person or for anyone else in the family, the other people now becoming caregivers. We're used to this. And for someone after a stroke or traumatic brain injury, now they have mobility changes. And so, we work on addressing those. But thinking on how those things now become a barrier for engaging with community and accessing things, something as simple as their pharmacy. Dr Albin: I hear a lot of “this is a fluid situation,” but there's hope here because these are places that we can intervene and that we can really champion brain health throughout this fluid situation. Which kind of brings me to what we're going to close out with, which is, I'm going to have you do a little thought exercise, which is that you find a magic lamp and a genie comes out. And we'll call this the brain health genie. The genie says that they are going to grant you one wish for the betterment of brain health. Daniel, I'll start with you. What is the one thing that you think could really move the needle on promoting and maintaining brain health? Dr Correa: I will jump on nutrition and food access. If we could somehow get rid of food insecurity and have access to whole and fresh foods for everyone, and people could go back to looking at opportunities from their ancestral and cultural experiences to cook and make whole-food recipes from their own cultures. Using something like the Mediterranean diet and the mind diet as a framework, but not looking at those as cultural barriers that we somehow all have to eat a certain way. So, I think that would really be the place I would go to first that would improve all of our brain health. Dr Albin: I love that. So, wholesome eating. Rana, how about you? One magic wish. Dr Said: I think traumatic brain injury prevention. I think it's so- it feels so within our reach, and it just always is so heart-hurting when you think that wearing helmets, using seatbelts, practicing safety in sports, gun safety---because we know unfortunately that in pediatric patients, firearm injury is the leading cause of traumatic brain injury. In our older patients, fall reduction. If we could figure out how to really disseminate the need for preventative measures, get everyone really on board, I think this is- the genie wouldn't have to work too hard to make that one come true. Dr Albin: I love that. As a neurointensivist, I definitely feel that TBI prevention. We could talk about this all day long. I really wish we had a longer bit of time, but I really would direct all of our listeners to this fantastic article where you give really practical advice. And so again, today I've been interviewing Drs Daniel Correa and Rana Said about their article on bridging the gap between brain health guidelines and real-world implementation, written with Dr Justin Jordan. This article appears in the most recent issue of Continuum on the disorders of CSF dynamics. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much for our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. We hope you've enjoyed this subscriber-exclusive interview. Thank you for listening.

EAU Educational Platform UROLUTS associate editor Dr. Manuela Tutolo talks to guidelines panel chair Prof. Gernot Bonkat on updates on EAU Guidelines for urological infections. This discussion took place during EAU25 in Madrid, Spain. For more updates on functional urology, please visit our educational platform UROLUTS.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Revoyez les points clefs à retenir concernant les traitements de l'obésité avec les analogues du GLP1 : sémaglutide, tirzépatide.Au cours de ce podcast, vous reverrez : ✅ Les modalités d'action des GLP1✅ A qui et comment les prescrire ? ✅ Quels sont les ES et les Contre indications ? ✅ Que se passe t'il quand on les arrête ?

WOKE MEDICINE: Canadian Nurses Association Goes FAR LEFTBecome a supporter of this podcast: https://www.spreaker.com/podcast/radio-baloney-the-richie-baloney-show--4036781/support.

Preparing for First Contact: Dive into the intriguing discussion on humanity's readiness for potential contact with extraterrestrial intelligence. A new research paper from the University of St. Andrews outlines how NASA and the global scientific community should gear up for a future where we might detect technological signatures from alien civilizations. Explore the proposed strategies for addressing misinformation, cultural interpretations, and the psychological impacts of such a monumental discovery.- Exoplanet Discovery: L9859 System: Discover the exciting announcement of a fifth rocky planet orbiting the red dwarf star L9859. This new addition to the system, located within the optimistic habitable zone, offers a unique opportunity to study planetary formation and evolution. Learn about the characteristics of these terrestrial planets and their potential for atmospheric studies with the James Webb Telescope.- Russia's Ionosphera M Satellites: Unpack the details of Russia's recent launch of the Ionosphera M satellites, designed to enhance our understanding of space weather. Find out how these satellites will contribute to improving forecasting and monitoring of the ionosphere, a crucial layer of Earth's atmosphere that affects satellite operations and radio communications.- Innovative Mars Mission Concept: Skyfall: Get captivated by the revolutionary Skyfall mission concept, which proposes deploying a fleet of scout helicopters to Mars. This innovative approach aims to gather critical data about the Martian surface and subsurface, paving the way for future human exploration. Discover how this idea builds on the success of previous Mars missions and could transform our exploration strategies.For more cosmic updates, visit our website at astronomydaily.io. Join our community on social media by searching for #AstroDailyPod on Facebook, X, YouTube Music Music, TikTok, and our new Instagram account! Don't forget to subscribe to the podcast on Apple Podcasts, Spotify, iHeartRadio, or wherever you get your podcasts.Thank you for tuning in. This is Anna signing off. Until next time, keep looking up and stay curious about the wonders of our universe.✍️ Episode ReferencesExtraterrestrial Intelligence Preparation[University of St. Andrews](https://www.st-andrews.ac.uk/)L9859 Exoplanet Discovery[NASA TV](https://tess.gsfc.nasa.gov/)Ionosphera M Satellites Launch[Russian Space Agency](https://www.roscosmos.ru/)Skyfall Mars Mission Concept[NASA TV](https://www.jpl.nasa.gov/)Astronomy Daily[Astronomy Daily](http://www.astronomydaily.io/)Become a supporter of this podcast: https://www.spreaker.com/podcast/astronomy-daily-space-news-updates--5648921/support.

It's one thing to recognize red flags in your relationships. It's another thing to know what to do after that.In this episode, you'll learn:Five spectrums to consider when determining how serious a red flag is.Guidelines for determining if a particular red flag is something that needs to be confronted or self-managed.How to grow in awareness of red flags without getting overwhelmed or scared to get close to others.Links we mentioned in this episode:Download "Is This Normal? 15 Red Flags You May Be Missing in Your Relationships" by Lysa TerKeurst here.Sign up for a $10 webinar on September 4 at 7 p.m. ET with the Chosen team to learn about attachment styles and foster better communication with your children — no matter their age. Have a question for Lysa, Jim, or Joel? Leave us a message, and it could be answered on one of our future podcast episodes! Start here.Click here to download a transcript of this episode.Go deeper: Listen to "Red Flags We Shouldn't Ignore in Relationships."Listen to "Here Is Your Permission To Set Boundaries" With Jim Cress.Watch "Difficult vs. Destructive Relationships."

NZ First's spoken about defunding sporting bodies that support trans inclusion - but its 2023 manifesto also spoke about making people healthier by promoting exercise and sport programmes including 'assisting people into sport that can't be involved' - surely those two sentiments juxtapose each other.

Under government direction, Sport New Zealand has scrapped guidelines for the inclusion of transgender people in community sport. The removal comes after a review showing the principles did not reflect legitimate community expectations that sport should prioritise fairness and safety. New Zealand First is claming full credit for the change as its coalition partners struggled to explain why the change was needed. Russell Palmer reports.

Happy July! This month for the July 2025 episode of the RCEM Learning Podcast Rob covers for Andy and discussed two PEM papers with Dave - looking at the role of parental concern in predicting paediatric critical illness and one looking at clearing the paediatric C-spine with CT imaging alone. Becky and Chris finish up their two part deep dive through a guideline looking at the management of acute behavioural disturbance and we then end with New Online! If you'd like to email us, please feel free to do so here. After listening, complete a short quiz to have your time accredited for CPD at the RCEMLearning website! (02:39) New in EM - Parental concern and paediatric critical illness Association between caregiver concern for clinical deterioration and critical illness in children presenting to hospital: a prospective cohort study (Mills et al., 2025) (18:01) Guidelines for EM - Acute Behavioural Disturbance in Emergency Departments (Part Two) RCEM - Acute Behavioural Disturbance in Emergency Departments (RCEM, 2025) [PDF] (43:37) New in EM - Paediatric C-spine clearance with CT alone An analysis of potential cervical spine clearance in children with computed tomography alone (Russell et al., 2025) (01:04:51) New Online – new articles on RCEMLearning for your CPD Zygomatic Complex and Nasal Injury - Jonathan Whittaker Learning from Deaths - Liz Herrieven Kishan Indrakumar, Thomas Moore, Dominique Tiriant, Mayank Nagar, Preetibah Ratenavelu, Arnav Singh - Prescribing in Pregnancy - A Practical ED Guide

The removal of Sport New Zealand's community sport trans guidelines are sparking debate around who wins and who loses protection. The principles around allowing participation based on gender identity were scrapped following a Government directive. Sportstalk host D'Arcy Waldegrave unpacks the situation further. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Kelly is referred to physical therapy six days after coronary artery bypass graft (CABG) surgery. She reports mild fatigue but denies chest pain or shortness of breath. Her resting heart rate is 85 bpm, and her blood pressure is 125/80 mmHg. The therapist plans to begin light aerobic exercise as part of her cardiac rehabilitation. Which of the following is the MOST appropriate guideline to follow during this session?A) Monitor for a target heart rate of 70–80% of her age-predicted maximumB) Avoid upper extremity exercises to minimize sternal stressC) Limit aerobic exercise to a maximum of 1–2 METs during this phaseD) Emphasize light aerobic exercise with an intensity below 13 on the Borg RPE scaleTEXT OUR TEAM:(727) 732-4573

Labour says the removal of trans-inclusive community sport guidelines is kicking the rainbow community while it's down. Labour MP Shanan Halbert spoke to Corin Dann.

The government has directed Sport NZ to scrap its guidelines for how to make community sport more inclusive for transgender people. Sports Minister Mark Mitchell spoke to Ingrid Hipkiss.

The Sports Minister's standing up for a coalition-based decision directing Sport New Zealand to remove its community sport trans guidelines. The 2022 principles allowed people to play community sports according to their gender identity. Sport Minister Mark Mitchell told Mike Hosking most fair-minded Kiwis would agree with the move, which honours safety and fairness. He says as part of a New Zealand First coalition agreement, they decided not to dictate what sporting bodies should be doing, saying the bodies themselves know best. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Implementing a Cardiology Quality Incentive Program to Improve Guideline-Directed Medical Therapy.

Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.

China has released its first national standards aimed at regulating school meal providers, part of a broader effort to improve food safety for the country's more than 230 million schoolchildren following a series of incidents that have sparkedpublic concern.中国发布了首部旨在规范学校餐食供应商的国家标准。在一系列引发公众关注的事件发生后，中国正致力于改善全国2.3亿多名学童的食品安全，该标准便是这一广泛努力的一部分。The "Guidelines for the Management of School Meal Service Providers", issuedby the State Administration for Market Regulation, will take effect on Dec 1 and apply to companies that prepare and deliver meals to primary and secondary schools as well as kindergartens.国家市场监督管理总局发布的《学校餐食服务供应商管理指南》将于12月1日生效，适用于为中小学及幼儿园准备和配送餐食的企业。The guidelines are designed to address food safety risks across the entire supplychain, from menu planning and ingredient procurement to food preparation, delivery and emergency response, officials said.有关部门负责人表示，该指南旨在应对整个供应链中的食品安全风险，涵盖从菜单规划、食材采购到食品制作、配送及应急响应等各个环节。"School meal provision involves wide coverage and multiple steps and has become a key area of supervision," said Qu Hao, an official with the administration,in an interview with China Central Television. "The guidelines offer clear, standardized instructions for schools and meal providers to follow."国家市场监督管理总局官员曲昊在接受中央电视台采访时表示：“学校餐食供应覆盖面广、环节多，已成为监管的重点领域。该指南为学校和餐食供应商提供了明确、规范的操作指引。”The new rules require providers to appoint food safety directors and dedicated inspection staff, conduct daily safety checks and analyze risks monthly. Staple ingredients such as rice, flour and cooking oil must be purchased from designatedsuppliers, and all batches of ingredients must undergo testing, including checks for pesticide residue.新规定要求供应商任命食品安全总监和专职检验人员，进行每日安全检查并每月分析风险。大米、面粉、食用油等主食食材必须从指定供应商处采购，且所有批次的食材都必须经过检测，包括农药残留检测。Food preparation processes will be monitored through "smart kitchen" systems that allow parents and schools to view operations in real time, while samples from each meal must be retained for at least 48 hours for safety checks. Delivery vehicles must be sealed, registered with authorities and equipped with GPS tracking.食品制作过程将通过“智慧厨房”系统进行监控，家长和学校可实时查看操作情况，同时每顿餐食的样本必须留存至少48小时以备安全检查。配送车辆必须密封、在有关部门登记并配备GPS追踪装置。If food safety issues are detected, providers must immediately initiate recall procedures and report incidents to local regulators.如发现食品安全问题，供应商必须立即启动召回程序，并向当地监管部门报告事件。The guidelines come as Chinese authorities move to strengthen oversight of school meals following recent incidents. In one case, more than 200 children at a kindergarten in Tianshui, Gansu province, were found to have elevated blood lead levels after kitchen staff used diluted industrial pigments in meals. Six people have been arrested and an investigation is ongoing.此前发生的一系列事件后，中国有关部门正加强对学校餐食的监管，此次指南的出台便是在此背景下进行的。在甘肃天水的一所幼儿园，厨房工作人员在餐食中使用稀释的工业色素，导致200多名儿童血铅水平升高。目前已有6人被捕，调查仍在进行中。The Ministry of Education has urged local education departments to use the summer break to conduct safety inspections and train school administrators and canteen staff in food safety management before the new semester begins.教育部已督促地方教育部门利用暑假进行安全检查，并在新学期开始前对学校管理人员和食堂工作人员进行食品安全管理培训。Authorities are also encouraging schools to offer affordable day care services during the summer using public facilities while reminding parents to remain vigilant when choosing summer camps and after-school programs to protect children'swell-being.有关部门还鼓励学校利用公共设施在暑期提供价格合理的日托服务，同时提醒家长在选择夏令营和课后项目时保持警惕，以保障儿童的健康福祉。The ministry has stressed that schools are not allowed to conduct classes duringthe summer vacation, delay the break or start the fall semester early, and should limit homework assigned over the summer.教育部强调，学校不得在暑假期间开展课程、推迟假期或提前开始秋季学期，且应限制暑假作业量。China's efforts to tighten oversight of school meal services aim to ensure "safety on the tip of the tongue" for millions of students, regulators said, as the government works to address public concerns over food safety and child welfare.监管部门表示，中国加强对学校餐食服务的监管，旨在确保数百万学生“舌尖上的安全”，政府正着力解决公众对食品安全和儿童福利的关切。school meal providersn.学校餐食供应商/skuːl miːl prəˈvaɪdəz/food safety risksn.食品安全风险/fuːdˈseɪfti rɪsks/

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-442 Overview: Listen in as we review the USPSTF's recently proposed recommendations for screening women who are at risk for developing osteoporosis. Gain confidence to navigate these changes and engage patients in shared decision-making to ensure timely, evidence-based preventive care. Episode resource links: JAMA. 2025;333(6):498–508. doi:10.1001/jama.2024.27154 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-442 Overview: Listen in as we review the USPSTF's recently proposed recommendations for screening women who are at risk for developing osteoporosis. Gain confidence to navigate these changes and engage patients in shared decision-making to ensure timely, evidence-based preventive care. Episode resource links: JAMA. 2025;333(6):498–508. doi:10.1001/jama.2024.27154 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

In this episode, we explore the halachic complexities surrounding the concept of trapping animals on Shabbat. What defines an animal as domesticated? When does bringing an animal indoors cross into forbidden territory? We discuss key opinions from major halachic sources about handling household pets, birds, and stray animals, and clarify the role of intent, animal behavior, and the size of a home or courtyard in determining permissibility. 

EAU edu platform UROLUTS associate editor Dr. Manuela Tutolo talks to guidelines panel members Prof. Chris Harding and Prof. Salvador Arlandis on the 2025 updates on EAU Guidelines for female LUTS. This expert discussion took place during EAU25 in Madrid, Spain.For more updates on functional urology, please visit our educational platform UROLUTS.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

This podcast episode discusses the evolution and current state of battlefield medicine, focusing on the Tactical Combat Casualty Care (TCCC) guidelines, training tiers, and the importance of evidence-based practices. The conversation highlights the challenges faced in implementing these guidelines and the ongoing efforts to improve trauma care in combat situations. Key updates to the TCCC curriculum and the logistics of providing medical care in the field are also addressed, emphasizing the need for continuous improvement and adaptation in military medicine.Listen ad-free with a premium membership on Spotify, Apple Podcast, or Patreon.TakeawaysThe majority of casualties occur in the pre-MTF environment due to hemorrhage.Improvements in battlefield trauma care have led to increased survival rates.Evidence-based medicine is crucial for developing TCCC guidelines.The TCCC curriculum consists of four training tiers for different levels of medical personnel.Recent updates to TCCC guidelines focus on airway management and TBI care.Logistics remain a significant challenge in providing timely medical care in combat.The committee emphasizes the importance of adapting guidelines based on new evidence.Training for combat medics must prioritize effective interventions for hemorrhagic shock.There is a need for consensus on triage methods in mass casualty situations.Continuous updates and training resources are essential for maintaining high standards in military medicine.Chapters00:00 Introduction to Battlefield Medicine02:40 Guidelines and Evidence-Based Practices04:55 TCCC Curriculum and Training Tiers07:47 Updates and Changes in TCCC Guidelines10:21 Current Challenges and Future Directions13:05 TCCC and Evidence Grading15:42 Logistics and Implementation Challenges17:58 Conclusion and ResourcesThank you to Delta Development Team for in part, sponsoring this podcast.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more content, go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

❌100% FREE VIDEO TRAINING (2025) ❌ New Method To Control Alcohol in 48 Hours ➡️ https://www.soberclear.com/video/?el=podcast

If you're constantly exhausted, it's not just stress, it's what you're putting on your plate. In this episode, we break down how processed foods, poor eating habits, and modern hustle culture are draining your energy and disconnecting you from your body's natural rhythm. Learn how intuitive eating, Ayurvedic principles, and real, seasonal foods can restore your vitality, sharpen your mind, and reconnect you to your intuition. This isn't about dieting.. It's about waking up.00:00 Welcome to the Woman Warrior Podcast02:31 Intuitive Eating and the Koshas03:39 Upcoming Events and Announcements10:55 Wellness Check-In27:56 Food as Medicine36:59 Endurance and the Overworked Lifestyle38:06 Natural Foods vs. Processed Foods40:06 The Seven Layers of Tissue41:07 The Importance of Hydration43:50 Blood and Invigoration45:32 Muscle and Confidence49:25 Fat Tissue and Love54:43 Bones and Structure58:39 Nervous System and Completeness01:00:36 Hormones and Creativity01:02:11 Guidelines for Intuitive Eating01:20:19 Final Thoughts Be sure to Like and Subscribe for more! For more information, please visit: https://www.womenswarriorsacademy.com Follow us on Instagram! Satyavani: https://www.instagram.com/satyavanigayatri/Prajna: https://www.instagram.com/kprajnamittleider/

In this episode, Dr. Zachary Dietch, transplant surgeon at Northwestern Medicine, shares the remarkable case of a liver retransplant for a patient with a recent cancer history, made possible through innovative tools like organ perfusion and bypass techniques. He also discusses how Northwestern is helping to redefine transplant eligibility for cancer patients through data-driven, patient-centered decisions.

Dr. Lyudmila Bazhenova is back on the podcast to discuss the latest update of the living guideline on therapy for stage IV NSCLC without driver alterations. She shares the studies the Expert Panel reviewed in the first- and second-line settings, including NIPPON, HARMONi-2, and DUBLIN-3. Although these studies do not impact the existing guideline recommendations, Dr. Bazhenova provides context and comments on ongoing trials that will influence the next iteration of the living guideline. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01062 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you back on the show today, Dr Bazhenova. Dr. Lyudmila Bazhenova: It's my pleasure to be here. Brittany Harvey: And then before we discuss this guideline update, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer without driver alterations is updated on an ongoing continuous basis. So what prompted this latest update to the recommendations? Dr. Lyudmila Bazhenova: Living ASCO guidelines are designed to keep pace with rapidly evolving evidence that impacts treatment of our patients with lung cancer. As a committee, we are tasked with regular review of the published literature and determine if the new data warrants changes to existing recommendations. So in this recently published update, we evaluated new trials related to treatment of patients with metastatic lung cancer without driver alterations. Brittany Harvey: Excellent. Thank you for that explanation of the process. So, you just mentioned that the panel reviewed new trials for this update. So, which particular updated evidence did the panel review on first-line treatment options for patients with good performance status across histology and PD-L1 expression status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: For the first-line treatment option for patients without driver alterations, two studies met our criteria for review. One was the NIPPON trial from Japan, the second was the HARMONi trial. None of those two trials resulted in change in our guidelines, but I think they are giving us some additional information that would be useful for the way we treat patients with non–small cell lung cancer without driver alterations. For example, if we take those patients, we currently have several treatment options as a first line. One is monotherapy immunotherapy. You can give pembrolizumab as an example, and that was based on the KEYNOTE-024 and KEYNOTE-042 trials. Then we have a platinum doublet plus immunotherapy, and there are several trials that did that pathway. And then we have also an option of giving our patients dual IO immunotherapy combination, such as CheckMate 9LA and POSEIDON. At this point, we do not have any randomized trials comparing those three treatment modalities head-to-head. And the NIPPON trial was interesting to us because it was the first trial to compare CheckMate 9LA regimen, which is again, dual immunotherapy plus chemo, versus KEYNOTE-189 or KEYNOTE-407, which is a chemotherapy plus immunotherapy. And as a result of the study, while chemotherapy plus ipilimumab-nivolumab led to numerically higher overall survival, the difference was not statistically significant. And what is concerning in that trial is that we saw a higher number of treatment-related death occurring in nivolumab and ipilimumab arm compared to the pembrolizumab-chemotherapy arm. As a matter of fact, the trial was terminated early because of the increased risk of death. If you look at the treatment-related death in CheckMate 9LA, the 9LA study reported the treatment-related death to be 2%, and then in the NIPPON trial, the treatment-related death was 7%. Why is that happening? It's really difficult to say. The study was done in Japan. Maybe there is some pharmacogenomic differences between global population and Japan population. But certainly the higher rate of adverse events needs to be taken into account. Another interesting thing about this trial is that it did not show any differences in a subset analysis for patients with squamous histology as well as PD-L1 negative tumor. So while this does not change our current guidelines and CheckMate 9LA treatment still remains an appropriate treatment option, it kind of raises the possibility that this combination could be associated with a higher toxicity. And we do have a randomized US-based trial that is ongoing, and we are hoping that eventually we will be able to answer that question after the trial will be completed. The second trial we reviewed is HARMONi-2. So HARMONi-2 was a randomized, double-blind study which is conducted primarily in China, looking at bispecific PD-L1 and VEGF antibody called ivonescimab. And that took patients who were PD-L1 positive, as defined as more than 1% expression, and patients were randomized to pembrolizumab versus bispecific ivonescimab. And the study was positive. It showed improvement in median progression-free survival of 11 months versus almost 6 months in bispecific versus pembrolizumab. There were, however, higher grade 3 events in the ivonescimab arm. At this point, we are not changing our recommendations because this trial was done in an ex-US population, and we are awaiting a similar trial ongoing in the United States before we change recommendations and decide if ivonescimab needs to be included in our guidelines. Brittany Harvey: This context is very helpful when clinicians think through the data behind these options. And it's important that the panel reviews this evidence, even if it doesn't prompt a change to the recommendations. And we'll await results of those trials that you mentioned to further inform this guideline. So then beyond those studies for first line, what updated evidence did the panel review for second-line and subsequent treatment options for patients with good performance status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: So for second line, only one trial met the criteria, and that was DUBLIN-3. DUBLIN-3 is a phase 3 single-blind randomized trial comparing docetaxel versus docetaxel plus plinabulin. And the study enrolled patients with second or third line. They have to have had platinum-based chemotherapy and progressed. Plinabulin is an interesting compound. It's a small molecule tubulin binder that prevents polymerization of tubulin and appears to impact dendritic cell maturation and T-cell activation. This study enrolled 559 patients, randomly assigned them to two groups. And one important information about this study is that was a study that was envisioned before immunotherapy became a standard mainstream treatment for first-line therapy. And only 20% of patients had prior PD-1 exposure. So therefore, the results of that study need to be taken into context of this population no longer existing in the United States because we use PD-L1 inhibitors in the first line. And we saw that interesting in the plinabulin arm had lower rates of neutropenia but higher rates of serious adverse events. And at this point, we are not changing our guidelines for mainly two reasons. Number one, low number of patients that received prior treatment with first-line immune checkpoint inhibitors, as well as a modest overall survival benefit of this trial. Brittany Harvey: Understood. I appreciate you describing that study as well and why that evidence didn't prompt a change to those particular recommendations. So then, what should clinicians know as they implement this living guideline, and how does this new evidence impact clinicians and patients? Dr. Lyudmila Bazhenova: At this point, none of the studies that we reviewed resulted in a change in guidelines. We are still waiting for more global results from some of the studies that I highlighted. It shows that there's still a lot of questions we need to be answering in those patients. And I'm hoping that with future clinical trials, we will be able to definitively maybe recommend one treatment over another. But at this point, all the treatments that I mentioned before remain appropriate for patients with stage IV non–small cell lung cancer without driver alterations. Brittany Harvey: Definitely. And then you just mentioned that there's still a lot of outstanding questions in this field. You've mentioned a couple different studies where we're awaiting evidence. Beyond those that you already mentioned, what is the panel examining for future updates to this living guideline? Dr. Lyudmila Bazhenova: Right now, our next task is to come up with a full guidelines update. ASCO have certain rules for the guidelines committee members. And so we are gearing for a full guideline update, which hopefully will be ready by the end of 2025. Brittany Harvey: Excellent. We'll look forward to that full update of the living guideline, and we'll still await results of these ongoing trials to further inform this living guideline. So I want to thank you so much for your work to rapidly and continuously update this living guideline, and thank you for the time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Are you confident when increasing the vertical dimension? How do you plan, stage, and sequence a full-mouth case safely? What's the right deprogramming method—leaf gauge, Kois appliance, or something else? Dr. David Bloom joins Jaz in this powerhouse episode to demystify the real-world process of increasing vertical dimension. With decades of experience in comprehensive dentistry, David shares how he approaches diagnosis, bite records, temporization, and final restorations—with predictability and confidence. https://youtu.be/gAaP0VYP84s Watch PDP232 on YouTube Protrusive Dental Pearl: Pick one occlusal philosophy and stick with it until you understand it well through real cases. Once you're confident, stay open to other approaches—hearing different views will make you smarter, more flexible, and a better dentist. If you are looking to get started with the foundations of Occlusion, check out our comprehensive Online Occlusion Course. Highlights of this episode: 00:00 Trailer 00:55 Introduction 04:43 Guest Introduction: Dr. David Bloom 10:25 Equilibration Techniques Explained 11:18  Interjection #1 15:50  Opening Vertical Dimension vs. Orthodontics 18:06 Interjection #2 23:05 Whitening and Restorative Solutions 25:27 Guidelines for Raising Vertical Dimension 25:52 Interjection #3 29:28 Midroll 32:49 Guidelines for Raising Vertical Dimension 36:06 Visual Try-In and Adapting Vertical Dimension 40:16 Case Planning and Execution 41:16 Interjection #4 43:42 Case Planning and Execution 50:23 Material Preference for Provisionals 52:00 Bite Registration and Final Adjustments 55:06 Do's and Don'ts for Clinicians 57:15 Conclusion and Resources 58:59 Outro Key Takeaways Vertical Dimension and Adaptation: Opening the vertical dimension in dentistry can be challenging, especially for edentulous patients who lack proprioception. However, with proper planning and understanding of occlusion, the human body can adapt remarkably well. Occlusal Philosophy: It's important to learn one occlusal philosophy well, whether it's Kois, Dawson, or another. Understanding different approaches can make you a more rounded clinician, as different patients may benefit from different methods. Equilibration and Deprogramming: Equilibration is crucial for idealizing occlusion by eliminating interferences. Deprogramming helps in achieving centric relation, a stable and repeatable position for the condyles, which is essential for successful equilibration. Orthodontics vs. Vertical Dimension: Deciding between orthodontics and opening the vertical dimension depends on the specific case. For example, pre-aligning patients with orthodontics might be necessary to address a restricted envelope of function. Testing and Adaptation: Testing the vertical dimension with transitional materials like composite can help patients adapt before moving to definitive restorations. Experienced clinicians may sometimes proceed directly to final restorations based on their judgment and diagnostic steps. Get CE/CPD for this episode only on the Protrusive Guidance App.

In this episode of the International Enneagram Association podcast, Seth “Creek” Creekmore and Ahmad Wazir continue their conversation with Flemming Christensen, founder and owner of Think About It and The Enneagram Institute of Denmark. They talk more about his book, “The Enneagram and why your blind type matters,” and his approach to the Enneagram. He highlights shadow work, which illuminates what we are not aware of about ourselves, and explores it within each Enneagram type. He also discusses the distinction between primary type and blind type.Connect with us:Web: internationalenneagram.orgIEA Enneagram Experience 2025: ieaexperience.comJoin the email list: administration@internationalenneagram.orgIEA Conference Proposal Submission Information & Guidelines: internationalenneagram.org/wp-content/uploads/2024/07/2025-Proposal-Submission-Information-Guidelines.pdfIEA Global Podcast Proposal Submission Form: forms.gle/Q48QXSwQ3zDfDJaJAFlemming Christensen:Web: flemmingchristensen.comTrainings: flemmingchristensen.com/trainingThe Enneagram Life Theme: flemmingchristensen.com/enneagram-life-theme.htmlBook: “The Enneagram and why your blind type matters”IG: @flemmingchristensencomFB: Flemming ChristensenLinkedIn: Flemming ChristensenSeth "Creek" Creekmore: IG: @_creekmorePod: Fathoms | An Enneagram PodcastPod: Awareness to Action Enneagram PodcastPod: Delusional Optimism with Dr. BAhmad Wazir:IG: @ahmadwazir19Pod: Totem ConfidenceAephoria Partners:Web: aephoriapartners.comFB: Aephoria Partners Consulting

Welcome back to another episode of the Online Warriors Podcast! This week we have a very special episode! The gang talks about the latest in Gaming and Entertainment! - New Nintendo E-Shop Guidelines (4:01) - Borderlands 4 Character Drop (11:48) - Microsoft Shuts Down Perfect Dark and Everwilds (22:02) - The Last of Us Part 2 Chronological Release (30:02) Then we talk about what the gang has been up to: - Techtic watches Jurassic World Rebirth (37:02) - Nerdbomber watches Megan 2.0 (42:49)   Special shoutout to our Patreon Producer: Steven Keller!   We'd like to thank each and every one of you for listening in every week. If you'd like to support the show, you can drop us a review on your favorite podcast platform or, if you're feeling extra generous, drop us a subscribe over at Patreon.com/OnlineWarriorsPodcast. We have three tiers of subscriptions, each of which gives you some awesome bonus content! As always, we appreciate you tuning in, and look forward to seeing you next week! Stay safe and healthy everyone! Find us all over the web: Online Warriors Website: https://www.onlinewarriorspodcast.com Online Warriors Twitter: https://twitter.com/onlinewarriors1 Illeagle's Twitter: https://twitter.com/OWIlleagle86 Nerdbomber's Twitter: https://twitter.com/OWNerdbomber Techtic's Twitter: https://twitter.com/OWTechtic Facebook: https://www.facebook.com/onlinewarriorspodcast Instagram: https://www.instagram.com/onlinewarriorspodcast/ YouTube: https://www.youtube.com/channel/UCwOwzY6aBcTFucWEeFEtwIg Merch Store: https://onlinewarriorspodcast-shop.fourthwall.com/

  This month, we're diving in deep on the U.S. approval of lenacapavir for PrEP -- both the promise it offers in expanding HIV prevention options and the current uncertainty around access, both in the U.S. and abroad. We also discuss growing concern within the HIV clinical community that our gold-standard guidelines for HIV treatment, care, and prevention may be rousted loose from their long-standing home within the Office of AIDS Research at the U.S. National Institutes of Health. And Laura Waters shares what she's most eager to learn about at IAS 2025, the global HIV science meeting that is taking place as this episode drops.   Please support our podcast by visiting the transcript, which includes links to the many references we mention in this episode: https://www.thebodypro.com/podcast/hiv/future-hiv-care-lenacapavir-prep-guidelines-july-2025   The podfolx: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

In this episode of the International Enneagram Association podcast, Seth “Creek” Creekmore and Ahmad Wazir speak with Flemming Christensen, founder and owner of Think About It and The Enneagram Institute of Denmark, about his work with the Enneagram. In this first part of the conversation, we get to know Fleming as he shares how he was introduced to the Enneagram, what drew him to it and how his understanding of it has evolved through the 20+ years of teaching it. He also discusses his approach on using the Enneagram as an approach to life rather than just a tool. Connect with us:Web: internationalenneagram.orgIEA Enneagram Experience 2025: ieaexperience.comJoin the email list: administration@internationalenneagram.orgIEA Conference Proposal Submission Information & Guidelines: internationalenneagram.org/wp-content/uploads/2024/07/2025-Proposal-Submission-Information-Guidelines.pdfIEA Global Podcast Proposal Submission Form: forms.gle/Q48QXSwQ3zDfDJaJAFlemming Christensen:Web: flemmingchristensen.comTrainings: flemmingchristensen.com/trainingBook: “The Enneagram and why your blind type matters”IG: @flemmingchristensencomFB: Flemming ChristensenLinkedIn: Flemming ChristensenSeth "Creek" Creekmore: IG: @_creekmorePod: Fathoms | An Enneagram PodcastPod: Awareness to Action Enneagram PodcastPod: Delusional Optimism with Dr. BAhmad Wazir:IG: @ahmadwazir19Pod: Totem ConfidenceAephoria Partners:Web: aephoriapartners.comFB: Aephoria Partners Consulting

Today's Topics: 1, 2, 3, 4) Association of Exorcists issues a document on errors it sees during exorcisms https://spiritdaily.org/blog/news/association-of-exorcists-issues-document-on-what-it-sees-as-errors

The BBC's Director General Tim Davie has apologised after a review found the Corporation failed to disclose that the documentary 'Gaza: How To Survive A Warzone' was narrated by the child of a Hamas official. Separately, the former Masterchef presenter Gregg Wallace said he was deeply sorry for any distress his behaviour caused after dozens of allegations against him were upheld. Also: Constance Marten and Mark Gordon are found guilty the manslaughter of their newborn daughter after a retrial. And a 61-year-old Flymo lawnmower is set to be inducted in a hall of fame.

In this episode, Tyler sits down with Hanna Thompson to discuss a critical yet often overlooked topic in EMS—eating disorders. Drawing from personal experience and clinical insight, they explore how these conditions present both medically and behaviorally, especially in prehospital and interfacility transport settings. They break down the subtle physical signs that EMS providers can look for—such as Russell's sign, lanugo, unexplained bradycardia, and electrolyte disturbances—and emphasize the importance of sensitive history taking. The conversation also dives into the dangers of refeeding syndrome, slow correction strategies, fluid choice, and the clinical significance of thiamine, magnesium, and phosphate replacement. What You'll Learn: How eating disorders can manifest in EMS calls Why you may be treating the consequences, not the disorder itself Red flags like bradycardia, lanugo, and Russell's sign How to handle refeeding syndrome safely Why dextrose, fluids, and electrolyte replacement should be approached cautiously The connection between electrolyte shifts and seizures or arrhythmias Key Takeaway: Patients with eating disorders are medically and psychologically fragile. In EMS, we often encounter them through the effects of the disorder—not the diagnosis itself. Recognizing subtle clues and avoiding aggressive interventions could save a life. Resources Mentioned: Hannah's blog on EMS considerations in eating disorders Data on post-COVID spikes in eating disorder incidence Guidelines for electrolyte correction and refeeding syndrome Disclaimer: This podcast is for educational purposes only and not a substitute for clinical protocols or medical direction. Always consult your agency's guidelines and medical control.

Pain during a cesarean section isn't a new problem. But for a long time, it's been a hidden one. In England, a patient named Susanna not only brings the problem to doctors' attention, but also tries to solve it. To get full access to this show, and to other Serial Productions and New York Times podcasts on Apple Podcasts and Spotify, subscribe at nytimes.com/podcasts.To find out about new shows from Serial Productions, and get a look behind the scenes, sign up for our newsletter at nytimes.com/serialnewsletter.Have a story pitch, a tip, or feedback on our shows? Email us at serialshows@nytimes.com

Dr. Rob and Marriage and Family Therapist and CSAT Arlene Rosen continue their discussion about discernment counseling. They consider how to determine what each person needs throughout the collaborative divorce process, how to protect children and pets throughout the journey, and realistic timelines when addiction is a factor in a relationship. Arlene shares advice, resources, and a message of hope and healing in the collaborative divorce process.    TAKEAWAYS: [1:22] Determining what each person needs throughout the collaborative divorce. [5:42] Child welfare versus child safety in court order agreements.  [8:10] Timeline possibilities when addiction is at play.  [11:20] Handling chronic lying in a legal setting.  [15:55] A message of hope in the collaborative divorce process. [18:09] Is there a simple way to know that I should get divorced?  [23:00] Guidelines for an effective separation period.  [29:35] Determining the right next step based on your current stage of life.  [32:32] Navigating divorce in a non-legal partnership.    RESOURCES: Sex and Relationship Healing @RobWeissMSW Sex Addiction 101  Seeking Integrity Free Sexual Addiction Screening Assessment Partner Sexuality Survey Arlene Rosen Seeking Integrity Podcasts are produced in partnership with Podfly Productions.    QUOTES: “You can make agreements about what will be talked about your addiction in your divorce.”  “Why do more damage when you've decided not to live together anymore?”  “The collaborative divorce process is simply more respectful.”  “The collaborative divorce process has the most opportunity for people to get back together.”